Harrow initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Harrow (HROW) with a Buy rating and $57 price target Harrow is a commercial-stage company focused on the development and commercialization of ophthalmic pharmaceutical products for the U.S. market, the analyst tells investors in a research note. The firm sees “rapid growth” for Harrow, driven by its portfolio of branded ophthalmic products. It believes the company will continue to make “meaningful and sensible acquisitions to enrich its ophthalmic product offerings.”